TherapeuticsMD (TXMD) adopted a royalty-only model in 2025, earning $3.0M in license revenue but incurring a net loss of $569K. Ongoing litigation and reliance on royalties raise concerns about its sustainability and future funding needs.

NodeGuardian

2026-04-17 04:25:24

Abstract generation in progress

TherapeuticsMD (TXMD) transitioned to a royalty-only model in 2025, reporting $3.0M in license revenue but also a net loss of $569K. The company faces significant going concern doubts due to ongoing litigation with Mayne Pharma and its reliance on royalty income. Future sustainability hinges on securing additional financing and growing its royalty streams.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
189.23K Popularity
#
Gate13thAnniversaryLive
653.76K Popularity
#
AltcoinsRallyStrong
7.31M Popularity
#
AnthropicvsOpenAIHeatsUp
1.06M Popularity
#
KalshiFacesNevadaRegulatoryClash
458.99K Popularity

Sitemap

TXMD: 2025 saw improved results from royalty revenue, but litigation and liquidity risks threaten viability

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

AltcoinsRallyStrong

AnthropicvsOpenAIHeatsUp

KalshiFacesNevadaRegulatoryClash

Pin